Acura Pharmaceuticals to Host Third Quarter 2013 Financial Results Conference Call on November 5, 2013

(firmenpresse) - PALATINE, IL -- (Marketwired) -- 10/29/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating , today announced that the Company plans to report financial results for the third quarter of 2013 following the close of financial markets on Monday, November 4, 2013. The Company will host a conference call to discuss the results on Tuesday, November 5, 2013 at 8:30 a.m. ET.

To participate in the live conference call, please dial 877-879-6207 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 2215110.

A replay of the call will be available beginning November 6, 2013 at 11:30 a.m. ET and ending on November 27, 2013 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 2215110.

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® technologies. In June 2011, the U.S. Food and Drug Administration approved OXECTA® which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products including other opioids and its IMPEDE® technology for pseudoephedrine hydrochloride products.

The trademark OXECTA® is owned by Pfizer Inc.



Contact:

847-705-7709


847-705-7709

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 29.10.2013 - 10:00 Uhr
Sprache: Deutsch
News-ID 310130
Anzahl Zeichen: 0

contact information:
Town:

PALATINE, IL

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 144 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Acura Pharmaceuticals to Host Third Quarter 2013 Financial Results Conference Call on November 5, 2013"
steht unter der journalistisch-redaktionellen Verantwortung von

Acura Pharmaceuticals, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Cli ...

PALATINE, IL -- (Marketwired) -- 09/29/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION® hydrocodone bitartrate with acetaminophen (AVERSION H/A) develo ...

Acura Pharmaceuticals Announces Third Quarter 2013 Financial Results ...

PALATINE, IL -- (Marketwired) -- 11/04/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine ...

Acura Pharmaceuticals Announces Distribution of Nexafed(R) by Rite Aid Pharmacie ...

PALATINE, IL -- (Marketwired) -- 11/04/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that NEXAFED [pseudoephedrine hydrochloride (HCl)], its next generation pseudoephedrine with abuse deterrent technology, will now be stocked by R ...

Alle Meldungen von Acura Pharmaceuticals, Inc.